Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 12/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.36 |
| ▸ | PSEN1 | P49768 | 3/20 | 0.36 |
| ▸ | PSEN2 | P49810 | 3/20 | 0.36 |
| ▸ | APH1B | Q8WW43 | 3/20 | 0.36 |
| ▸ | NCSTN | Q92542 | 3/20 | 0.36 |
| ▸ | APH1A | Q96BI3 | 3/20 | 0.36 |
| ▸ | PSENEN | Q9NZ42 | 3/20 | 0.36 |
| ▸ | KIF11 | P52732 | 2/20 | 0.35 |
| ▸ | CTPS1 | P17812 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.34 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.33 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24259145 | 0.85 | NR1H4 (0.43) | NR1H4SUCNR1 | |
| SCHEMBL24259503 | 0.80 | NR1H4 (0.43) | NR1H4PSEN1SUCNR1 | |
| SCHEMBL25993555 | 0.69 | NR1H4 (0.48) | NR1H4 | |
| SCHEMBL24259140 | 0.69 | NR1H4 (0.39) | NR1H4 | |
| SCHEMBL24259083 | 0.68 | NR1H4 (0.46) | NR1H4 | |
| SCHEMBL24259369 | 0.68 | CTPS1 (0.43) | NR1H4CYP2D6PSEN1PSEN2APH1B | |
| SCHEMBL24258731 | 0.68 | FAAH (0.37) | NR1H4CYP2D6PSEN1PSEN2APH1B | |
| SCHEMBL24259123 | 0.66 | NR1H4 (0.39) | NR1H4 | |
| SCHEMBL24258818 | 0.66 | NR1H4 (0.44) | NR1H4 | |
| SCHEMBL25993492 | 0.64 | NR1H4 (0.50) | NR1H4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11713312-B2 | Substituted bicyclic compounds as farnesoid X receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2023-08-01 | — | — | US | disclosed |
| US-20220135550-A1 | SUBSTITUTED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2022-05-05 | — | — | US | disclosed |
| US-11254663-B2 | Substituted bicyclic compounds as farnesoid X receptor modulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2022-02-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220135550-A1 | SUBSTITUTED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | FXR1, NR1H4, FXR2 | NR1H4 2/4885CYP2D6 1210/4885PSEN1 1401/4885 |
| US-11254663-B2 | Substituted bicyclic compounds as farnesoid X receptor modulators | FXR1, NR1H4, FXR2 | NR1H4 2/4885CYP2D6 1210/4885PSEN1 1401/4885 |
| US-11713312-B2 | Substituted bicyclic compounds as farnesoid X receptor modulators | FXR1, NR1H4, FXR2 | NR1H4 2/4885CYP2D6 1210/4885PSEN1 1401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.